Trials / Completed

CompletedNCT01911715

A Study to Explore the Routes of Elimination of MDV3100

A Phase I Open-label Study to Investigate the Mass Balance and Biotransformation of a Single Oral 160 mg (100 µCi) Dose of 14C-MDV3100 (ASP9785) in Healthy Male Subjects

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 6 (actual)

Sponsor: Astellas Pharma Europe B.V. · Industry
Sex: Male
Age: 18 Years – 55 Years
Healthy volunteers: Accepted

Summary

A study to investigate the excretion routes of radio-labelled MDV3100.

Conditions

Healthy Subjects
Pharmacokinetics of MDV3100

Interventions

Type	Name	Description
DRUG	MDV3100	Oral

Timeline

Start date: 2011-04-01
Primary completion: 2011-07-01
Completion: 2011-07-01
First posted: 2013-07-30
Last updated: 2013-07-30

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT01911715. Inclusion in this directory is not an endorsement.